Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval
暂无分享,去创建一个
[1] A. Patel,et al. Physical activity, obesity, and bladder cancer incidence , 2023, Cancer Causes & Control.
[2] C. Dinney,et al. The current status of gene therapy in bladder cancer , 2023, Expert review of anticancer therapy.
[3] Sam S. Chang,et al. Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer , 2022, Current Oncology Reports.
[4] Anirban P. Mitra,et al. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial , 2021, European Urology.
[5] G. Andriole,et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. , 2020, The Lancet. Oncology.
[6] L. Egevad,et al. The natural history of untreated muscle‐invasive bladder cancer , 2020, BJU international.
[7] C. Dinney,et al. The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside , 2018, World Journal of Urology.
[8] Anirban P. Mitra,et al. Lentiviral interferon: A novel method for gene therapy in bladder cancer , 2018, Molecular therapy oncolytics.
[9] K. Ogan,et al. Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] H. Grossman,et al. Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette–Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer , 2016, Annals of Surgical Oncology.
[11] C. Dinney,et al. Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG , 2015, Bladder cancer.
[12] C. Dinney,et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. , 2013, The Journal of urology.
[13] C. Dinney,et al. Direct cytotoxicity produced by adenoviral-mediated interferon α gene transfer in interferon-resistant cancer cells involves ER stress and caspase 4 activation , 2011, Cancer Gene Therapy.
[14] R. Connor,et al. Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer. , 2007, Cytokine & growth factor reviews.
[15] C. Dinney,et al. Interferon-α Induces TRAIL Expression and Cell Death Via an IRF-1-Dependent Mechanism in Human Bladder Cancer Cells , 2007 .
[16] B. Bochner,et al. Adenoviral Receptor Expression of Normal Bladder and Transitional Cell Carcinoma of the Bladder , 2007, Urologia Internationalis.
[17] A. Sabichi,et al. Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. , 2006, The Journal of urology.
[18] C. Dinney,et al. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation , 2006, Cancer Gene Therapy.
[19] C. Dinney,et al. Intravesical Ad-IFNα Causes Marked Regression of Human Bladder Cancer Growing Orthotopically in Nude Mice and Overcomes Resistance to IFN-α Protein , 2004 .
[20] M. Lamfers,et al. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells , 2004, Cancer Gene Therapy.
[21] B. Wiedenmann,et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. , 2003, Journal of the National Cancer Institute.
[22] B. Czerniak,et al. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer , 2002, Cancer Gene Therapy.
[23] G. Demers,et al. Interferon α2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers , 2001, Cancer Gene Therapy.
[24] C. Dinney,et al. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] A. Sagalowsky,et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. , 1999, Cancer research.
[26] J. Nickel,et al. Relative efficacy of various exogenous glycosaminoglycans in providing a bladder surface permeability barrier. , 1998, The Journal of urology.
[27] C. Bucana,et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. , 1998, Cancer research.
[28] R. Burnham,et al. Multidisciplinary chronic pain management in a rural Canadian setting. , 2010, Canadian journal of rural medicine : the official journal of the Society of Rural Physicians of Canada = Journal canadien de la medecine rurale : le journal officiel de la Societe de medecine rurale du Canada.
[29] L. Trümper. From bench to bedside , 2005, Medizinische Klinik.
[30] C. Dinney,et al. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[31] H. Engler,et al. Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium , 2001, Gene Therapy.